Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 21, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

This lesion most likely represents a benign process rather than a malignant one, given its small size, stable nature, and location consistent with post-surgical changes following partial nephrectomy for chromophobe renal cell carcinoma. The key finding is that the lesion was present on CT imaging just 1.5 months after partial nephrectomy and has remained stable without significant growth. According to the European Association of Urology guidelines 1, the most important criterion for malignant lesions is the presence of contrast enhancement or restriction, which is not explicitly mentioned in this case.

Key Considerations

  • The lesion's size (3mm) and stability over time are highly suggestive of a benign entity, as malignant lesions typically demonstrate progressive growth 1.
  • The location of the lesion in the fat anterior to the psoas and caudal to the lower pole of the left kidney is consistent with potential post-surgical changes following partial nephrectomy 1.
  • The American Society of Clinical Oncology clinical practice guideline 1 notes that as many as 25% of small renal masses are benign renal cortical tumors, such as oncocytoma, metanephric adenoma, and angiomyolipoma.
  • The ACR Appropriateness Criteria for post-treatment follow-up and active surveillance of clinically localized renal cell carcinoma 1 recommend rigorous imaging and clinical follow-up for patients on active surveillance, with subsequent surgical or minimally invasive treatment reserved for those with tumors that progress.

Recommendations

  • Continued surveillance is reasonable to ensure ongoing stability, but the long-term stability of this small lesion strongly favors a benign etiology rather than recurrent or metastatic disease.
  • Imaging surveillance of the chest and abdomen should be performed according to established guidelines, such as those recommended by the European Association of Urology 1 and the American College of Radiology 1.

From the Research

Lesion Characteristics

  • The lesion is 3mm in size, located anterior to the psoas, and caudal to the lower pole of the left kidney.
  • It has been present for 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC).

Malignant or Benign Process

  • There is no direct evidence from the provided studies to confirm whether the lesion represents a malignant or benign process 2, 3, 4, 5, 6.
  • However, the studies suggest that chromophobe RCC generally has a good prognosis and typically presents with a well-defined homogeneous mass and hypo-vascular soft tissue enhancement 2.
  • The presence of a small lesion near the site of a previous partial nephrectomy for chromophobe RCC could be indicative of a local recurrence, but this would require further investigation to confirm 4.

Diagnostic Approaches

  • FDG PET scanning has been shown to be useful in identifying malignancy and variations in grade in soft tissue masses, and could potentially be used to direct biopsy of the lesion 3.
  • Immunohistochemical studies, such as those using antibody panels, may be useful in distinguishing chromophobe RCC from other types of renal tumors, including clear cell RCC 6.

Clinical Implications

  • The management of the lesion would depend on the results of further diagnostic tests, such as biopsy or imaging studies, to determine whether it represents a malignant or benign process.
  • If the lesion is found to be malignant, treatment options may include surgical resection or other therapies, depending on the stage and grade of the tumor 4, 5.

Related Questions

Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?
What is the significance of a 3 mm nodule near the left kidney in a patient with a history of partial nephrectomy for Chromophobe renal cell carcinoma (RCC)?
Is a 3 mm nodule appearing 1 month after partial nephrectomy for T1a chromophobe (renal cell carcinoma) located in the fat anterior to the psoas muscle below the lower pole of the kidney scar tissue?
What is the significance of a 3 mm nodule in the fat anterior to the psoas muscle, present one month post-partial nephrectomy for chromophobe Renal Cell Carcinoma (RCC) and persisting over three years?
What is the significance of a 1.5 cm mass in the perinephric space adjacent to the surgical bed, 3 years after partial nephrectomy for a 1.3 cm chromophobe renal cell carcinoma (RCC) T1a?
What are the symptoms of encephalitis?
What are the causes of phimosis?
Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?
Does a 3mm lesion anterior to the psoas, caudal to the lower pole of the left kidney, present since 1.5 months post-partial nephrectomy for stage T1a low-grade Chromophobe Renal Cell Carcinoma (RCC), represent a malignant or benign process?
Can antibiotics be delayed until a lumbar puncture (LP) is performed?
What are the most notable studies on Acute Respiratory Distress Syndrome (ARDS)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.